Frontier Pharma Parkinson’s Disease

1

• Frontier Pharma Parkinsons Disease Identifying
  and Commercializing

2
Summary
Parkinsons Disease (PD) is the second most
common neurodegenerative disease after
Alzheimers disease, affecting around 7.4 million
people worldwide. It is caused by the progressive
loss of dopamine-producing neurons in the
substantia nigra within the basal ganglia. The
main motor symptoms are tremors, bradykinesia and
rigidity, although symptoms vary between
individuals. As the disease progresses to more
advanced stages, increasing symptoms and
complications develop, which can cause severe
disability in patients.
3

The current market offers a number of anti-PD
treatment options which provide symptomatic
relief. Levodopa is currently the gold standard
therapy, with other drug classes including
dopamine agonists and Monoamine Oxidase B (MAO-B)
inhibitors also used to treat early and advanced
cases. With no current treatment showing
effectiveness in delaying the course of the
disease, PD remains incurable. The high unmet
need for a disease-modifying therapy is reflected
in the pipeline, where a high proportion of
early-stage first-in-class programs target the
potential pathogenic mechanisms underlying
neurodegeneration.
4

Scope
PD is a crowded market with many neuromodulatory
drug classes available. However, a
disease-modifying therapy with neuroprotective
effects is yet to be developed. - What are the
primary mechanisms that are thought to contribute
to neuronal death? - What are the major barriers
facing the development of investigational
neuroprotective candidates? Analysis reveals a
high level of innovation and diversity in the
pipeline, with 121 first-in-class programs acting
on 57 unique molecular targets. Neuromodulatory
targets remain the dominant target family,
particularly in the late-stage pipeline. - What
are the first-in-class families with a
significant presence? - How well do they align
with the underlying pathways governing neuronal
death in PD?
5

Scope
PD is a crowded market with many neuromodulatory
drug classes available. However, a
disease-modifying therapy with neuroprotective
effects is yet to be developed. - What are the
primary mechanisms that are thought to contribute
to neuronal death? - What are the major barriers
facing the development of investigational
neuroprotective candidates? Analysis reveals a
high level of innovation and diversity in the
pipeline, with 121 first-in-class programs acting
on 57 unique molecular targets. Neuromodulatory
targets remain the dominant target family,
particularly in the late-stage pipeline. - What
are the first-in-class families with a
significant presence? - How well do they align
with the underlying pathways governing neuronal
death in PD?
6
Some of the first-in-class targets have a
potentially stronger chance of being translated
into novel treatments for PD. - What is the
scientific rationale behind these targets? How do
they perform in Preclinical studies? - What are
the commonly used disease models and the
parameters measuring neuroprotective effects in
PD animal studies? Deals involving first-in-class
PD products are more likely to be made in earlier
stages of development than non-first-in-class
deals. - What is the dominant molecular target
in the PD deals landscape? - What are the
promising first-in-class products still available
for future licensing?
W www.bharatbook.com , T  91 22 27810772,
27810773, E  poonam_at_bharatbook.com
7
Reasons to By
This report will allow you to - - Understand the
current clinical and commercial landscape by
considering the proposed pathogenic processes
underlying PD neurodegeneration, diagnosis,
prognosis, and the available treatment options
and their usage in early and advanced PD. -
Visualize the composition of the PD market to
highlight the current unmet needs in order to
gain a competitive understanding of the key
opportunities. - Analyze the PD pipeline and
stratify by stage of development, molecule type,
and molecular target - the diversity of molecular
targets in the pipeline is extremely encouraging
due to the multifaceted nature of PD. - Assess
the therapeutic potential of first-in-class
targets using a proprietary matrix that assesses
and ranks first-in-class products according to
clinical potential. - Target the most promising
and innovative PD products for early-stage
investment by analyzing trends in licensing and
co-development deals and accessing a curated list
of first-in-class therapies potentially open to
deal-making opportunities.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  poonam_at_bharatbook.com
8
Table of Contents

• Executive Summary 4
• The Case for Innovation 5
• Clinical and Commercial Landscape 9
• Disease Pathophysiology 12
• Assessment of Pipeline Product Innovation 35
• First-in-Class Target Matrix Assessment 46
• First-in-Class Target Evaluation 49
• Deals and Strategic Consolidations 72
• Research Methodology 93
• Licensing and Co-development Deals 95

W www.bharatbook.com , T  91 22 27810772,
27810773, E  poonam_at_bharatbook.com
9
To view the full Executive Summary and Table
of Contents, please visit Frontier Pharma
Parkinsons Disease Contact Us-Call India
91-22-27810772/73Email id info_at_bharatbook.com
Website www.bharatbook.com Our Blog
https//www.bharatbook.com/blog/

W www.bharatbook.com , T  91 22 27810772,
27810773, E poonam_at_bharatbook.com